LINC-ROR regulates myocardial ischemia/reperfusion injury via targeting of miR-129-5p/Hook3 axis
Abstract
Purpose: To investigate the underlying mechanism of long intergenic non-protein coding RNA (LINC- ROR) in myocardial ischemia/reperfusion (I/R) injury.
Methods: Rat H9C2 cells were used to establish the model of hypoxia/reoxygenation (H/R). Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. The proportion of apoptotic H9C2 cells was evaluated using flow cytometry. Luciferase reporter experiments and RNA pull-down assays were used to determine the relationships among LINC-ROR, miR-129-5p, and hook microtubule tethering protein 3 (Hook3), while QRT-PCR and western blots were used to investigate the relationship between LINC-ROR and the expression and activation of Hook3 and proteins of the PI3K/AKT/mTOR pathway.
Results: LINC-ROR was elevated under H/R stimulation. The viability of H9C2 cells decreased, and cell apoptosis was induced after H/R treatment. These latter effects were abrogated by the down- regulation of LINC-ROR. Luciferase reporter results and RNA pull-down showed that LINC-ROR served as the miR-129-5p sponge, and miR-129-5p was bound to Hook3 RNA directly. Moreover, overexpression of LINC-ROR increased Hook3 protein level by serving as miR-129-5p sponge. Furthermore, the overexpression of LINC-ROR activated PI3K/Akt/mTOR pathway by regulating Hook3.
Conclusion: LINC-ROR increases in cardiomyocytes with H/R injury. Down-regulation of LINC-ROR alleviates myocardial I/R injury via miR-129-5p/Hook3 axis. Therefore, LINC-ROR is a potential therapeutic target for myocardial I/R injury.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
